On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a fruitful discussion with patient advocates from the AMRO region about the pandemic’s situation reports and challenges related to individuals with thalassaemia in these areas.
Oktober 12, 2020
Oktober 2, 2020
EdiGene Application of CRISPR/Cas 9 Gene-editing Therapy ET-01 For β-Thalassaemia Has Been Accepted For Review
Oktober 27, 2020
Überprüfen Sie auchSchließen